Form 4 for STLN Starling Oncology, Inc.
Accepted 2023-11-22 00:00:00 ET · period of report 2023-11-21 · accession 0001628280-23-039911 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-22 | 2023-11-21 | STLN | Virnich Daniel | CEO | D - Sale to Iss | $2.19 | -4,322 | 729.6K | -0.6% | -$9,465 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-11-21 | D | D | 4,322 | $2.19 | 729,603 | D | — | — |